相关实验视频
Updated: Jul 23, 2025

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.0K
利用大数据的生存信息来统一风险分层相关的适应性免疫受体参数,用于多发性骨髓瘤
Hope J Wolmarans1, Vayda R Barker1, Andrea Chobrutskiy2
1Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Genes and immunity
|July 13, 2023
概括
这项研究确定了特定免疫受体 (CDR3) 和癌症丸抗原 (CTA) 与多发性骨髓瘤患者的生存相关的关系. 结果表明T细胞受体相互作用的约束,但T细胞受体α相互作用的灵活性,突出IGSF11作为潜在的抗原.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 计算生物学 计算生物学
背景情况:
- 多发性骨髓瘤在很大程度上是无法治愈的,尽管治疗方法得到了改进.
- 免疫疗法为多发性骨髓瘤提供了有前途的进展.
- 以前的研究发现了基于T细胞受体基因使用和HLA等位基因的生存差异.
研究的目的:
- 应用一个互补性评分算法来识别与生存相关的多个髓瘤相关的CDR3-CTA关系.
- 将这些发现与之前的T细胞受体基因使用和HLA等位基因数据重叠.
- 研究CTA IGSF11作为多发性骨髓瘤抗原的潜力.
主要方法:
- 利用一个互补性评分算法来分析CDR3-CTA关系.
- 将算法应用于多发性骨髓瘤患者数据.
- 已识别的免疫受体特征与先前的T细胞受体V/J基因段和HLA等位基因数据重叠.
主要成果:
- 确定了与多发性骨髓瘤生存差异相关的特定CDR3-CTA关系.
- 在TRA-抗原-HLA和TRB-抗原-HLA组合之间的约束和灵活性中观察到差异.
- 突出了CTA IGSF11作为多发性骨髓瘤免疫疗法的潜在抗原.
结论:
- 互补性评分可以识别多发性髓瘤中与生存相关的免疫受体-抗原相互作用.
- 免疫受体-抗原-HLA相互作用的独特模式可能会影响患者的存活率.
- IGSF11成为多发性骨髓瘤治疗策略的有希望的候选抗原.
相关概念视频
Cancer Survival Analysis
394
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
394
Comparing the Survival Analysis of Two or More Groups
226
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
226
Kaplan-Meier Approach
188
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
188
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

